ArticleOncogene2007
Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning-based meta-analysis of colorectal cancer and inflammatory bowel disease.PloS one · 2023Pooled it
- Genetic and Epigenetic Mechanisms in Serrated Adenocarcinomas and Classical Colorectal Carcinomas: An In Silico Study.Current issues in molecular biology · 2026Article
- Do Colorectal Serrated and Non-Serrated Adenocarcinomas Differ in Somatic Mutations and Clinicopathologic Features?Medicina (Kaunas, Lithuania) · 2025Article
- Exploring WNT pathway dysregulation in serrated colorectal cancer for improved diagnostic and therapeutic strategies.Frontiers in genetics · 2025Article
- TGFβ-Responsive Stromal Activation Occurs Early in Serrated Colorectal Carcinogenesis.International journal of molecular sciences · 2024Article
- Enhanced SREBP2-driven cholesterol biosynthesis by PKCλ/ι deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis.Nature communications · 2023Article
- The clinical relevance and prediction efficacy from therapy of tumor microenvironment related signature score in colorectal cancer.Frontiers in oncology · 2023Article
- Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer.Cancer cell international · 2022Article
- The EPH/Ephrin System in Colorectal Cancer.International journal of molecular sciences · 2022Review
- The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC).Frontiers in oncology · 2022Review
- Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.Cancers · 2021Article
- RosettaSX: Reliable gene expression signature scoring of cancer models and patients.Neoplasia (New York, N.Y.) · 2021Article
- A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients.NPJ precision oncology · 2021Article
- Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.Gastroenterology · 2021Review
- ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS production and melanoma metastasis.Oncogenesis · 2021Article
- Robust proportional overlapping analysis for feature selection in binary classification within functional genomic experiments.PeerJ. Computer science · 2021Article
- Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor.International journal of molecular sciences · 2020Review
- Review
- Review
- Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression profiling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by expression profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.
Indexed as
Identifiers
16819509What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.